Article thumbnail

Biological activity of a genetically modified BMP-2 variant with inhibitory activity

By Uwe Klammert, Joachim Nickel, Kristian Würzler, Christoph Klingelhöffer, Walter Sebald, Alexander C Kübler and Tobias Reuther
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). AK: TGF-beta1, FGF2, and receptor mRNA expression in suture mesenchyme and dura versus underlying brain in fusing and nonfusing mouse cranial sutures. Plast Reconstr Surg
  2. (2006). BMP and BMP inhibitors in bone.
  3. (2003). De Schepper AM: Pictorial essay. Myositis ossificans circumscripta. JBR-BTR
  4. (2004). Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum
  5. (2003). DM: Multiple joint and skeletal patterning defects caused by single and double mutations
  6. (2003). EM: Bone morphogenetic protein4 regulation in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res
  7. (2004). EM: Heterotopic ossification.
  8. (2003). EM: In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am
  9. (1998). Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop Relat Res
  10. (2000). Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet
  11. (1996). FS: Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva.
  12. (2003). FS: Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.
  13. (1996). FS: Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  14. (2001). HF: Disulfide bridge conformers of mature BMP are inhibitors for heterotopic ossification. Biochem Biophys Res Commun
  15. (2004). JA: Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype.
  16. (2003). KW: Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification. J Bone Miner Res
  17. (2000). Localization of the gene for fibrodysplasia ossificans progressiva (FOP) to chromosome 17q21-22. Genet Couns
  18. (2001). Lucotte G: Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva.
  19. (2003). Monsoro-Burq AH: BMP signals regulate Dlx5 during early avian skull development. Dev Biol
  20. (2004). Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model.
  21. (1998). TGF-beta signal transduction. Annu Rev Biochem
  22. (2003). The BMP antagonist Noggin regulates cranial suture fusion. Nature
  23. (2001). The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists.
  24. (2004). Transforming growth factor-beta isoform expression in the perisutural tissues of craniosynostotic rabbits. Cleft Palate Craniofac J
  25. (2000). W: BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.